Stephen Ellis

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Pilot candidate gene analysis of patients ≥ 60 years old with aortic stenosis involving a tricuspid aortic valve
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA
    Am J Cardiol 110:88-92. 2012
  2. ncbi Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients
    Michael R Elashoff
    CardioDx, Inc, 2500 Faber Place, Palo Alto, CA 94602, USA
    BMC Med Genomics 4:26. 2011
  3. ncbi Accreditation of hospitals for percutaneous coronary intervention on the basis of volume or clinical outcome using MEDPAR data sets: effect on patient mortality, cost and treatment accessibility
    S G Ellis
    The Cleveland Clinic Foundation, 9500 Euclid Avenue, F 25, Cleveland, OH 44195, USA
    J Invasive Cardiol 12:464-71. 2000
  4. ncbi Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Invasive Cardiol 19:404-9. 2007
  5. ncbi Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 106:1205-10. 2002
  6. ncbi Relation of polymorphisms in five genes to long-term aortocoronary saphenous vein graft patency
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiol 99:1087-9. 2007
  7. ncbi Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Ohio 44195, USA
    Catheter Cardiovasc Interv 67:541-5. 2006
  8. ncbi Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 45:1193-200. 2005
  9. ncbi Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 63:135-40. 2004
  10. ncbi Plaque that makes a patient vulnerable
    Stephen Ellis
    Sones Cardiac Catheterization Labs, Cleveland Clinic Foundation, F-25, One Clinic Center, 9500 Euclid Avenue, Cleveland, OH 44195-5066, USA
    J Invasive Cardiol 16:401. 2004

Research Grants

  1. Northeast Ohio Center for Cardiovascular Cell Therapy Research
    Stephen Ellis; Fiscal Year: 2007

Detail Information

Publications100

  1. ncbi Pilot candidate gene analysis of patients ≥ 60 years old with aortic stenosis involving a tricuspid aortic valve
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA
    Am J Cardiol 110:88-92. 2012
    ..Given the concerns regarding the problem of multiple statistical testing, validation studies are required to further assess these correlations...
  2. ncbi Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients
    Michael R Elashoff
    CardioDx, Inc, 2500 Faber Place, Palo Alto, CA 94602, USA
    BMC Med Genomics 4:26. 2011
    ..A non-invasive blood test that could reliably assess obstructive CAD likelihood would have diagnostic utility...
  3. ncbi Accreditation of hospitals for percutaneous coronary intervention on the basis of volume or clinical outcome using MEDPAR data sets: effect on patient mortality, cost and treatment accessibility
    S G Ellis
    The Cleveland Clinic Foundation, 9500 Euclid Avenue, F 25, Cleveland, OH 44195, USA
    J Invasive Cardiol 12:464-71. 2000
    ..We sought to ascertain the effect of credentialing hospitals for PCR, either on the basis of procedural volume or outcome, on clinical outcome, cost and accessibility to treatment, in states of varied population density...
  4. ncbi Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Invasive Cardiol 19:404-9. 2007
    ..We sought to ascertain and compare 12-month target vessel revascularization (TVR) rates for sirolimus-eluting Cyphertrade mark stents and bare-metal stents (BMS) when utilized to treat stenoses in diseased SVGs...
  5. ncbi Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 106:1205-10. 2002
    ..Creatine kinase (CK)-MB elevation after percutaneous coronary intervention (PCI) has been associated with subsequent cardiac death. The patients at risk, the timing of risk, and potential treatment implications are uncertain...
  6. ncbi Relation of polymorphisms in five genes to long-term aortocoronary saphenous vein graft patency
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiol 99:1087-9. 2007
    ..016), 7 polymorphisms in 5 genes were associated with SVG patency (p <0.01). In conclusion, these data represent an initial step toward the use of a personalized genetic approach to coronary revascularization...
  7. ncbi Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Ohio 44195, USA
    Catheter Cardiovasc Interv 67:541-5. 2006
    ..Retroperitoneal hemorrhage (RPH) is an infrequent but occasionally fatal complication of percutaneous coronary intervention (PCI). Therefore, it has been studied in relatively small numbers of patients...
  8. ncbi Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 45:1193-200. 2005
    ..We sought to evaluate the relationship between angiographic late loss and clinical outcomes in the drug-eluting stent era...
  9. ncbi Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 63:135-40. 2004
    ..Conversely, if the benefits of DESs are attenuated in routine practice, many groups of patients treated with BMSs may have nearly comparable results...
  10. ncbi Plaque that makes a patient vulnerable
    Stephen Ellis
    Sones Cardiac Catheterization Labs, Cleveland Clinic Foundation, F-25, One Clinic Center, 9500 Euclid Avenue, Cleveland, OH 44195-5066, USA
    J Invasive Cardiol 16:401. 2004
  11. ncbi Effects of long-term prednisone (> or =5 mg) use on outcomes and complications of percutaneous coronary intervention
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, F 25, Cleveland, OH 44195, USA
    Am J Cardiol 93:1389-90, A6. 2004
    ..Steroid use was not associated with increased risk of composite major ischemia events but was associated with a threefold risk (p = 0.01) of major vascular complications and a three- to fourfold risk (p = 0.026) of coronary perforation...
  12. ncbi Facilitated PCI in patients with ST-elevation myocardial infarction
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic, F25, 9500 Euclid Ave, Cleveland, OH 44195, USA
    N Engl J Med 358:2205-17. 2008
    ....
  13. ncbi Incidence, timing, and correlates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients followed for up to 3 years
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1043-51. 2007
    ..This study sought to study stent thrombosis with the paclitaxel-eluting Taxus stent...
  14. ncbi Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, F25, Cleveland, OH 44195, USA
    Eur Heart J 29:1625-34. 2008
    ....
  15. ncbi beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise
    S G Ellis
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 104:2685-8. 2001
    ..The cogency of such a conclusion is dependent on the ability to risk-adjust for the multiple differences in patients treated with and without BBs...
  16. ncbi Enhanced prediction of mortality after percutaneous coronary intervention by consideration of general and neurological indicators
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    JACC Cardiovasc Interv 4:442-8. 2011
    ..This study sought to improve methodology for predicting post-percutaneous coronary intervention (PCI) mortality...
  17. ncbi Impact of mitral regurgitation on long-term survival after percutaneous coronary intervention
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:315-8. 2002
  18. ncbi Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial
    Stephen G Ellis
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 147:E16. 2004
    ..We hypothesize that a strategy of early pharmacologic reperfusion therapy with abciximab alone or in conjunction with reduced-dose reteplase, followed by PCI will improve the outcome of patients eligible for primary PCI...
  19. ncbi Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent)
    Stephen G Ellis
    Cleveland Clinic, Department of Cardiology, Cleveland, Ohio 44195, USA
    JACC Cardiovasc Interv 2:1248-59. 2009
    ....
  20. ncbi 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial
    Stephen G Ellis
    Cleveland Clinic, Department of Cardiovascular Medicine, Cleveland, Ohio 44195, USA
    JACC Cardiovasc Interv 2:909-16. 2009
    ..The aim of this report was to evaluate 12-month outcomes of facilitated percutaneous coronary intervention (PCI) in the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial...
  21. ncbi Incremental progress? The roles of direct stenting and routine troponin measurement after percutaneous coronary intervention
    Stephen G Ellis
    Sones Cardiac Catheterization Labs, The Cleveland Clinic Foundation, F25, One Clinic Center, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 14:171-2. 2002
  22. ncbi Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting
    Stephen G Ellis
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:937-40. 2002
    ..06, p = 0.33), which is consistent with the results of prior randomized trials. ACE inhibitors appear to decrease late revascularization, possibly due to a reduction in restenosis after coronary stenting...
  23. ncbi Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 95:716-21. 2005
    ....
  24. ncbi Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis
    Inder M Singh
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Catheter Cardiovasc Interv 76:257-62. 2010
    ..We compared the long-term outcomes of drug-eluting stents (DES) versus bare-metal stents (BMS) for treatment of bare-metal in-stent restenosis (ISR)...
  25. ncbi Emergency coronary artery bypass surgery in the contemporary percutaneous coronary intervention era
    Niranjan Seshadri
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 106:2346-50. 2002
    ..Risk factors include female sex and a higher ACC/AHA score of the intervened lesion. However, morbidity and mortality of emergency CABG remain high even in the new millennium...
  26. ncbi Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    JACC Cardiovasc Interv 1:227-32. 2008
    ..We sought to examine the clinical outcomes of patients treated with drug-eluting stents (DES) compared with bare-metal stents (BMS) during primary angioplasty for ST-segment elevation myocardial infarction (STEMI)...
  27. ncbi Radial artery bypass grafts have an increased occurrence of angiographically severe stenosis and occlusion compared with left internal mammary arteries and saphenous vein grafts
    Umesh N Khot
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 109:2086-91. 2004
    ..The radial artery has been increasingly used in CABG. However, angiographic outcome data have been limited...
  28. ncbi Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention
    Deepak P Vivekananthan
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Cardiol 94:358-60. 2004
    ..Clopidogrel pretreatment attenuated the periprocedural increase in CRP by 65% and was independently associated with an attenuation in the CRP increase in a multivariate model...
  29. ncbi Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent
    Juhana Karha
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 98:616-8. 2006
    ..This finding was present in the BMS and SES groups and highlights the need for aggressive risk-factor modification after PCI...
  30. ncbi Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction
    Allen Jeremias
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 143:1040-5. 2002
    ..05-1.73, P =.02). CONCLUSIONS: This analysis of patients with chronic renal insufficiency undergoing PCI suggests that postprocedural CK-MB elevation is an independent predictor of late mortality even in the presence of renal dysfunction...
  31. ncbi Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction
    Albert W Chan
    Section of Interventional Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:132-6. 2002
    ....
  32. ncbi Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy--a propensity-adjusted analysis
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA
    Am Heart J 151:1031.e1-6. 2006
    ..1% vs 52.3%, P < .001) or significant myonecrosis (7.5% vs 21.8%, P < .001) was significantly lower among patients pretreated with statins. This difference remained significant after multivariable and propensity adjustment...
  33. ncbi Bare metal stent restenosis is not a benign clinical entity
    Michael S Chen
    The Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 151:1260-4. 2006
    ..Aggressive efforts, such as drug-eluting stents to decrease the incidence of unstable angina due to bare metal ISR, are warranted...
  34. ncbi Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency
    Allen Jeremias
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:1209-11. 2002
  35. ncbi GuardWire emboli protection device is associated with improved myocardial perfusion grade in saphenous vein graft intervention
    Jose E Exaire
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 148:1003-6. 2004
    ..5 or 3 had a statistically significant reduction in MACE (OR 0.36, 95% CI 0.14-0.87, P = .02). CONCLUSIONS: Compared with SVG-PCI without emboli protection, EPD significantly improved TMP and trended towards a reduction in MACE...
  36. ncbi Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting
    Philippe L L'Allier
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, USA
    Can J Cardiol 19:1041-6. 2003
    ..Most studies have demonstrated similar outcomes and a more favourable safety profile supporting this change in practice patterns...
  37. ncbi Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention
    Albert W Chan
    Section of Interventional Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 105:691-6. 2002
    ..65; 95% CI, 0.42 to 0.99; P=0.045). CONCLUSIONS: In this large study cohort, statin therapy among PCI patients seems to be associated with a significant mortality advantage at early and intermediate-term follow-up...
  38. ncbi Clopidogrel pharmacogenomics: next steps: a clinical algorithm, gene-gene interactions, and an elusive outcomes trial
    Patrick Gladding
    Cleveland Clinic, Cleveland, Ohio 44195, USA
    JACC Cardiovasc Interv 3:995-1000. 2010
    ..In this brief viewpoint article, we ask some pointed questions of our own and outline the pathway that needs to be taken for clinical translation to occur...
  39. ncbi In vivo analysis of the anatomical relationship of coronary sinus to mitral annulus and left circumflex coronary artery using cardiac multidetector computed tomography: implications for percutaneous coronary sinus mitral annuloplasty
    Arti J Choure
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 48:1938-45. 2006
    ..These anatomical features should be taken into consideration while selecting percutaneous treatment strategies for mitral valve repair...
  40. ncbi Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition
    Leslie Cho
    Department of Cardiology, Loyola University Medical Center, Maywood, Illinois 60153, USA
    Am J Cardiol 91:742-3. 2003
  41. ncbi Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Am Coll Cardiol 39:9-14. 2002
    ..Therefore, clopidogrel plus aspirin should replace ticlopidine plus aspirin as the standard antiplatelet regimen after stent deployment...
  42. ncbi Impact of female sex on outcome after percutaneous coronary intervention
    John H Chiu
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 148:998-1002. 2004
    ..However, there is a greater incidence of post-procedural bleeding complications among women...
  43. ncbi Drug-eluting versus bare-metal stents for treating saphenous vein grafts
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44114, USA
    Am Heart J 158:637-43. 2009
    ..Current data show conflicting results regarding safety and efficacy of drug-eluting stents (DES) versus bare-metal stents (BMS) for treating saphenous vein grafts (SVG). Our objective was to compare DES with BMS for SVG intervention...
  44. ncbi Stent-assisted detachable coil embolization of pseudoaneurysms in the coronary circulation
    Anjli Maroo
    Department of Cardiovascular Medicine, Section of Interventional Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 68:409-15. 2006
    ....
  45. ncbi Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F 25, Cleveland, OH 44195 USA
    Eur Heart J 27:413-8. 2006
    ..The optimal revascularization strategy in patients with symptomatic multivessel coronary artery disease (CAD) and previous coronary artery bypass grafting (CABG) remains unknown...
  46. ncbi Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial
    Gregg W Stone
    Department of Cardiology, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10032, USA
    JAMA 295:1253-63. 2006
    ..The effectiveness of drug-eluting stents in this setting has not been established...
  47. ncbi A meta-analysis of randomized trials of rescue percutaneous coronary intervention after failed fibrinolysis
    Taral N Patel
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 97:1685-90. 2006
    ..61, 95% confidence interval 0.91 to 14.27, p=0.07). In conclusion, rescue PCI in the setting of early fibrinolytic failure improves mortality, but this is tempered by a possible increase in the risk of thromboembolic stroke...
  48. ncbi Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial
    Gregg W Stone
    Department of Cardiology, Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY 10032, USA
    JAMA 294:1215-23. 2005
    ..Compared with bare metal stents, drug-eluting stents reduce restenosis in noncomplex lesions. The utility of drug-eluting stents has not been evaluated in more difficult stenoses...
  49. ncbi The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention
    Robert B Fathi
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 150:1190-7. 2005
    ..CONCLUSION: Although baseline us-CRP and GFR are both independent predictors of long-term death after PCI, in concert, they impart a markedly exaggerated hazard of mortality...
  50. ncbi Abciximab-facilitated percutaneous coronary intervention and long-term survival--a prospective single-center registry
    Sorin J Brener
    Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA
    Eur Heart J 24:630-8. 2003
    ..To identify predictors of use of abciximab and evaluate the long-term survival after percutaneous coronary intervention with or without abciximab in a broad spectrum of patients...
  51. ncbi Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes
    Juhana Karha
    The Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 98:906-10. 2006
    ..92, 95% confidence interval 0.69 to 1.23, p = 0.59). In conclusion, adjunctive use of platelet GP IIb/IIIa inhibitors in saphenous vein graft PCI does not appear to be associated with less myonecrosis or improved survival...
  52. ncbi Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial
    Sorin J Brener
    Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Am Coll Cardiol 39:377-86. 2002
    ..This study was designed to test the hypothesis that eptifibatide and reduced-dose tissue plasminogen activator (t-PA) will enhance infarct artery patency at 60 min in patients with acute myocardial infarction (AMI)...
  53. ncbi Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 92:1468-71. 2003
    ..3%, 7.5%, 8.1%, and 7.1%, respectively (p=0.71). The incidence of bleeding complications was 6.6%, 5.9%, 6.9%, and 7.3%, respectively (p=0.81). ACT did not independently predict either ischemic or hemorrhagic complications...
  54. ncbi Comparison of long-term survival following non-Q-wave creatine kinase elevation after percutaneous coronary intervention in patients discharged on a beta blocker versus those not so treated
    Stephen G Ellis
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:751-3. 2002
  55. ncbi Impact of drug-eluting versus bare-metal stents on mortality in patients with anemia
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195 0002, USA
    JACC Cardiovasc Interv 2:329-36. 2009
    ..Our aim was to assess the incidence of all-cause mortality in patients with anemia undergoing percutaneous coronary intervention (PCI) receiving drug-eluting stents (DES) or bare-metal stents (BMS)...
  56. ncbi Comparison of percutaneous versus surgical revascularization of severe unprotected left main coronary stenosis in matched patients
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiol 101:169-72. 2008
    ..Diabetes mellitus and advanced co-morbidity were the principal determinants of survival. These findings support the need for randomized trials with adequate follow-up to compare the 2 approaches...
  57. ncbi Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 40:1961-7. 2002
    ..The goal of this study was to assess the long-term impact of creatine kinase-MB isoform (CK-MB) elevation after percutaneous or surgical revascularization...
  58. ncbi Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 152:1051.e9-14. 2006
    ....
  59. ncbi The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients
    David S Lee
    Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 16:46-51. 2004
    ....
  60. ncbi LightTyper platform for high-throughput clinical genotyping
    Gurunathan Murugesan
    The Cleveland Clinic Foundation, Department of Clinical Pathology, OH 44195, USA
    Expert Rev Mol Diagn 5:457-71. 2005
    ..The initial experience presented here suggests the potential use of the LightTyper for high-throughput clinical genotyping...
  61. ncbi Creation of a large-scale genetic data bank for cardiovascular association studies
    Ramtin Agah
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 150:500-6. 2005
    ..A prerequisite for undertaking genetic association studies is the need for a genetic data bank with adequate DNA samples and a well-described clinical cohort...
  62. ncbi Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention
    Albert W Chan
    Section of Interventional Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 40:669-75. 2002
    ..46 to 0.87; p = 0.0054). CONCLUSIONS: Within this large prospective registry, beta-blocker use was associated with a marked long-term survival benefit among patients undergoing successful elective percutaneous coronary revascularization...
  63. ncbi Transradial catheterization: the road less traveled
    Nitin Barman
    The Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Cleveland, OH, USA
    J Invasive Cardiol 16:639-40. 2004
  64. ncbi Characterization of post-operative risk associated with prior drug-eluting stent use
    Saif Anwaruddin
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    JACC Cardiovasc Interv 2:542-9. 2009
    ..The aim of this study was to assess risk of inpatient surgery at any time after percutaneous coronary intervention (PCI) with drug-eluting stents (DES)...
  65. ncbi Drug-eluting stent fracture and acute coronary syndrome
    Adnan K Chhatriwalla
    Division of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cardiovasc Revasc Med 10:166-71. 2009
    ..Coronary stent fracture is an underrecognized entity but has been reported more frequently in the drug-eluting stent (DES) era. Nevertheless, the clinical implications of coronary stent fracture remain unclear...
  66. ncbi In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting?
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    J Am Coll Cardiol 49:849-54. 2007
    ....
  67. ncbi Clinical outcomes of drug-eluting versus bare-metal in-stent restenosis
    Inder M Singh
    Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 75:338-42. 2010
    ..28) were also not different. This study represents the largest analysis comparing drug-eluting to bare-metal ISR. On multivariable Cox proportional hazard analyses, drug-eluting and bare-metal ISR have similar long term outcomes...
  68. ncbi Drug-eluting stents: the beginning of the end of restenosis?
    Cameron Haery
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 71:815-24. 2004
    ..These stents will likely be used more and more as their indications evolve...
  69. ncbi Relation of myocardial perfusion to mortality after primary percutaneous coronary intervention
    Juhana Karha
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 95:980-2. 2005
    ..This observation has important implications for the methods of evaluating primary PCI results and the strategies used to improve myocardial reperfusion...
  70. ncbi Relation of inflammation and benefit of statins after percutaneous coronary interventions
    Albert W Chan
    Catheterization Laboratory, Department of Cardiology, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Circulation 107:1750-6. 2003
    ..We sought to examine the interrelationship between inflammation, statin use, and PCI outcomes...
  71. ncbi Is routine functional testing after coronary bypass surgery worthwhile?
    Michael S Lauer
    Department of Cardiovascular Medicine of the Cleveland Clinic Lerner College of Medicine of CWRU, Cleveland, Ohio, USA
    J Invasive Cardiol 18:153-4. 2006
  72. ncbi Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 52:1041-8. 2008
    ..Our purpose was to examine the incidence of all-cause mortality among drug-eluting stents (DES) and bare-metal stents (BMS) while adjusting for many confounding factors generally not considered in prior studies...
  73. ncbi Understanding and minimizing late thrombosis of drug-eluting stents
    Mark G Rabbat
    Department of Internal Medicine, Cleveland Clinic, OH 44195, USA
    Cleve Clin J Med 74:129-36. 2007
    ..The aim of this article is to review the incidence, predictors, pathology, and prevention of late thrombosis of drug-eluting stents...
  74. ncbi Renal failure after percutaneous coronary intervention is associated with high mortality
    Ritesh Gupta
    Division of Cardiology, Department of Medicine, University of Alabama, Birmingham, USA
    Catheter Cardiovasc Interv 64:442-8. 2005
    ..6% +/- 0.27% in those without any post-PCI renal insufficiency (P < 0.0001). Acute renal insufficiency after PCI is a strong and independent predictor of long-term mortality in patients who survived for 30 days after the procedure...
  75. ncbi Periprocedural myonecrosis: from a laboratory anomaly to a sentinel of risk
    Hitinder S Gurm
    Ital Heart J 4:1-3. 2003
  76. ncbi Impact of mild or moderate renal insufficiency on the intravascular ultrasonic analysis of chronic vascular response to paclitaxel-eluting and bare-metal stents (from the TAXUS IV, V, and VI trials)
    Jiro Aoki
    Columbia University Medical Center, New York, New York, USA
    Am J Cardiol 102:1009-16. 2008
    ..In conclusion, neointimal proliferation was less prominent and expansive vessel remodeling was more prominent after PES than BMS implantation, independent of the severity of renal dysfunction...
  77. ncbi Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial)
    Eugenia Nikolsky
    Cardiovascular Research Foundation, New York, New York 10022, USA
    Am J Cardiol 95:709-15. 2005
    ..Paclitaxel-eluting stents attenuate the increased risk associated with obesity, such that the intermediate-term prognosis after percutaneous coronary intervention is independent of weight...
  78. ncbi One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial
    Gregg W Stone
    The Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, 55 E 59th St, 6th Floor, New York, NY 10022, USA
    Circulation 109:1942-7. 2004
    ..The safety and efficacy of the slow-release, polymer-based, paclitaxel-eluting stent after implantation in a broad cross section of de novo coronary lesions at 1 year are unknown...
  79. ncbi A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease
    Gregg W Stone
    Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New York 10022, USA
    N Engl J Med 350:221-31. 2004
    ..Restenosis after coronary stenting necessitates repeated percutaneous or surgical revascularization procedures. The delivery of paclitaxel to the site of vascular injury may reduce the incidence of neointimal hyperplasia and restenosis...
  80. ncbi Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty (GUSTO II-B) Angioplasty Substudy
    Jacqueline E Tamis-Holland
    Division of Cardiology, St Luke s Roosevelt Hospital Center and Columbia University College of Physicians and Surgeons, New York, NY 10025, USA
    Am Heart J 147:133-9. 2004
    ..Direct angioplasty (PTCA) and thrombolytic therapy are the chief therapies for treating an ST-segment elevation myocardial infarction (MI)...
  81. ncbi Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists
    Wojciech Mazur
    Baylor College of Medicine and The Methodist Hospital, Houston, Tex, USA
    Am Heart J 143:594-601. 2002
    ..However, patients in whom high-risk features are present after stent placement are at increased risk of ischemic cardiac events even with abciximab treatment...
  82. ncbi Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial
    Mitchell J Ross
    Division of Cardiology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    J Am Coll Cardiol 42:981-8. 2003
    ..We sought to assess whether pre-procedural angiographic characteristics are associated with adverse clinical outcomes after coronary stenting with glycoprotein IIb/IIIa inhibition...
  83. ncbi Five common gene variants identify elevated genetic risk for coronary heart disease
    Lance A Bare
    Celera, Alameda, California 94502, USA
    Genet Med 9:682-9. 2007
    ....
  84. ncbi Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials
    Jeffrey W Moses
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10032, USA
    J Am Coll Cardiol 47:2164-71. 2006
    ....
  85. ncbi Impact of coronary culprit lesion calcium in patients undergoing paclitaxel-eluting stent implantation (a TAXUS-IV sub study)
    Issam Moussa
    Cardiovascular Research Foundation and Columbia University Medical Center, New York, NY, USA
    Am J Cardiol 96:1242-7. 2005
    ..30 and 0.26, respectively). In conclusion, implantation of paclitaxel-eluting stents in patients with de novo coronary lesions significantly reduced restenosis in patients with and without calcified lesions...
  86. ncbi Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy)
    Paul S Teirstein
    Scripps Clinic, La Jolla, California, USA
    Am J Cardiol 96:500-5. 2005
    ..By multivariate analysis, use of GP IIb/IIIa inhibitors during stenting with the TAXUS stent was an independent predictor of CK-MB increases >3 times the normal level. Further studies are warranted...
  87. ncbi Effect of uncoated stenting versus balloon angioplasty alone of long coronary (>20 mm) versus shorter narrowings on one-year event-free survival
    Fernando A Cura
    Department of Cardiology, Instituto Cardiovascular de Buenos Aires, Argentina
    Am J Cardiol 91:587-90. 2003
  88. ncbi Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery
    George Dangas
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York, USA
    J Am Coll Cardiol 45:1186-92. 2005
    ..Notably, the need for bypass graft surgery due to restenosis is reduced after TAXUS stent implantation in LAD lesions...
  89. ncbi Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease
    Alexandra J Lansky
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York, USA
    J Am Coll Cardiol 45:1180-5. 2005
    ..28 [95% CI 0.11 to 0.74], p = 0.01). CONCLUSIONS: The benefits of the paclitaxel-eluting stent in reducing clinical and angiographic restenosis are generalizable to women...
  90. ncbi Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial
    James B Hermiller
    St. Vincent's Hospital, Indianapolis, Indiana, USA
    J Am Coll Cardiol 45:1172-9. 2005
    ..CONCLUSIONS: The site-specific delivery of paclitaxel after coronary stent implantation is highly effective in reducing clinical and angiographic restenosis in patients with diabetes mellitus...
  91. ncbi Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 356:998-1008. 2007
    ..Such studies have been inconclusive because of their insufficient size, the use of historical controls, a limited duration of follow-up, and a lack of access to original source data...
  92. ncbi Impaired myocardial perfusion score and inflammatory markers in patients undergoing primary angioplasty for acute myocardial infarction
    J Emilio Exaire
    Instituto Nacional de Cardiologia, Mexico City, Mexico
    Arch Cardiol Mex 76:376-82. 2006
    ....
  93. ncbi Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial
    Ameet Bakhai
    Harvard Clinical Research Institute, Boston, Massachusetts, USA
    J Am Coll Cardiol 48:253-61. 2006
    ..The cost-effectiveness ratio for PES in the study population compares reasonably with that for other treatments that reduce coronary restenosis, including alternative drug-eluting stent platforms...
  94. ncbi Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial
    Jeffrey W Moses
    Columbia University Medical Center, New York, New York, USA
    J Am Coll Cardiol 45:1165-71. 2005
    ..97], p = 0.04). CONCLUSIONS: The use of the paclitaxel-eluting TAXUS stent was safe in patients with unstable ischemic syndromes, and was associated with marked reduction of ischemia-driven TLR and adverse cardiac events at one year...
  95. ncbi Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials
    Marco Roffi
    Division of Cardiology, University Hospital, Zurich, Switzerland
    Circulation 106:3063-7. 2002
    ..In the absence of mechanical emboli protection, this procedure is associated with high incidence of death and nonfatal ischemic events...
  96. ncbi The safety of a bivalirudin-based approach in patients undergoing rotational atherectomy
    Hitinder S Gurm
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan 48109 0311, USA
    J Invasive Cardiol 19:225-8. 2007
    ....
  97. ncbi ACCF/AHA/SCAI 2007 update of the Clinical Competence Statement on Cardiac Interventional Procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and
    Spencer B King
    Circulation 116:98-124. 2007
  98. ncbi "Crying fire in a theater" or a "confirmatory sighting?"
    Stephen G Ellis
    J Am Coll Cardiol 50:268-9. 2007
  99. ncbi Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial
    Giora Weisz
    Cardiovascular Research Foundation and Columbia University Medical Center, New York, New York 10032, USA
    J Am Coll Cardiol 47:1350-5. 2006
    ....
  100. ncbi Effect of catheter-based iridium-192 gamma brachytherapy on the added risk of restenosis from diabetes mellitus after intervention for in-stent restenosis (subanalysis of the GAMMA I Randomized Trial)
    Jeffrey W Moses
    Lenox Hill Heart and Vascular Institute and Cardiovascular Research Foundation, New York, New York 10021, USA
    Am J Cardiol 90:243-7. 2002
    ..The relative impact of this treatment is more pronounced in diabetic patients because it appears to neutralize the added risk of recurrent restenosis seen in proliferative diabetic lesions...

Research Grants2

  1. Northeast Ohio Center for Cardiovascular Cell Therapy Research
    Stephen Ellis; Fiscal Year: 2007
    ..End of Abstract) ..